[{"id":"1feb857d-51e5-4682-a570-aafec2b08650","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568680","created_at":"2022-10-06T14:56:16.043Z","updated_at":"2024-07-02T16:35:03.301Z","phase":"Phase 1","brief_title":"SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","source_id_and_acronym":"NCT05568680","lead_sponsor":"Verismo Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SynKIR-110"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-05-16"}]